Compare · MYMD vs NNNN
MYMD vs NNNN
Side-by-side comparison of MyMD Pharmaceuticals Inc. (MYMD) and Anbio Biotechnology (NNNN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MYMD and NNNN operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- NNNN is the larger of the two at $2.36B, about 15.9x MYMD ($149.1M).
- NNNN has hit the wire 1 time in the past 4 weeks while MYMD has been quiet.
- Company
- MyMD Pharmaceuticals Inc.
- Anbio Biotechnology
- Price
- $1.82-1.62%
- $15.80-13.33%
- Market cap
- $149.1M
- $2.36B
- 1M return
- -
- -39.68%
- 1Y return
- -
- +83.51%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2014
- 2025
- News (4w)
- 0
- 1
- Recent ratings
- 0
- 0
MyMD Pharmaceuticals Inc.
MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, engages in the development of drug candidates to treat autoimmune, and aging and age-related diseases. It is developing MYMD-1, a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel diseases, as well as to treat age-related illnesses such as, frailty and sarcopenia. The company is also developing Supera-CBD, a synthetic preclinical cannabidiol derivative that targets CB2 receptors. The company is based in Baltimore, Maryland.
Latest MYMD
- TNF Pharmaceuticals Trades Under New Ticker "TNFA"
- TNF Pharmaceuticals (Formerly MyMD Pharmaceuticals) Begins Trading Under New Nasdaq Stock Symbol "TNFA" Effective Before Market Open Today
- MyMD Pharmaceuticals Announces Corporate Rebranding To New Name TNF Pharmaceuticals, To Begin Under The New Trading Symbol "TNFA" Effective July 24, 2024
- MyMD Pharmaceuticals Announces Corporate Rebranding to New Name TNF Pharmaceuticals, Inc.
- SEC Form DEF 14A filed by MyMD Pharmaceuticals Inc.
- SEC Form 3 filed by new insider Friscia Stephen
- Latest Key Hires & Board Changes In Cannabis Industry: Canopy Growth, Acreage And More
- MyMD Pharmaceuticals Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- SEC Form S-3 filed by MyMD Pharmaceuticals Inc.
- Amendment: MyMD Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement
Latest NNNN
- SEC Form 6-K filed by Anbio Biotechnology
- SEC Form 6-K filed by Anbio Biotechnology
- Amendment: SEC Form 20-F/A filed by Anbio Biotechnology
- SEC Form 3 filed by new insider Song Suki
- SEC Form 3 filed by new insider Hartzler Nancy
- SEC Form 3 filed by new insider Lau Michael
- SEC Form 3 filed by new insider Tian Chris
- SEC Form 3 filed by new insider Xu Cany
- SEC Form 20-F filed by Anbio Biotechnology
- Anbio Biotechnology to Participate in KeyBanc Capital Markets Healthcare Forum